Cognition Therapeutics (CGTX) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cognition Therapeutics (CGTX) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 55.0% versus a loss of 75.6%. Neumora Therapeutics is the larger company by market cap ($89.4 million vs $83.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | NMRA |
|---|---|---|
| Share price | $0.8769 | $0.4757 |
| Market cap | $83.39M | $89.38M |
| 1-day change | -2.04% | -0.85% |
| YTD return | -35.04% | -73.42% |
| 1-year return | -55.03% | -75.61% |
| 5-year return | -92.63% | — |
| EPS (TTM) | $-0.17 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.05 | $3.65 |
| 52-week low | $0.55 | $0.45 |
| Distance from 52-week high | -57.22% | -86.97% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +279.75% | +1190.73% |
| Average volume | 534.62K | 1.20M |
| Shares outstanding | 95.09M | 187.90M |
| Employees | 14 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGTX has outperformed NMRA by 20.6 percentage points over the past year.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
CGTX vs NMRA FAQ
Which is bigger, Cognition Therapeutics or Neumora Therapeutics?
Neumora Therapeutics (NMRA) is larger, with a market capitalization of $89.38M compared with $83.39M for Cognition Therapeutics (CGTX).
Which stock has performed better over the past year, CGTX or NMRA?
CGTX returned -55.03% over the past 12 months, compared with -75.61% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.